LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Measuring glutathione in biological samples requires attention to oxidation, because GSH can convert to GSSG after sample collection. Blood and plasma samples are often treated with acid or alkylating agents to preserve the reduced form. Without stabilization, apparent GSH concentrations can fall while GSSG rises. Differences in sample type, handling delay, and deproteinization method can produce results that are not comparable across studies. Reporting preanalytical details is therefore important for interpreting findings.
Common analytical approaches include enzymatic recycling assays, high-performance liquid chromatography, and mass spectrometry. Enzymatic recycling measures total glutathione after converting GSSG back to GSH, while separation methods can quantify GSH and GSSG separately. Derivatization may be used to improve detection or stability during analysis. LC-MS/MS offers high specificity and can distinguish glutathione from related thiols and adducts. Each method has different sensitivity, throughput, and susceptibility to interference, so method selection depends on the study question and sample matrix.
Samples for glutathione analysis require careful handling because the compound oxidizes readily and can be consumed by enzymes after collection. Blood is often treated with acid or thiol-blocking agents soon after draw, and plasma should be separated quickly from red blood cells. Tissues are usually snap-frozen or extracted immediately. Aqueous solutions of glutathione are less stable than dry powder and degrade faster at neutral or alkaline pH, in light, or with dissolved oxygen. Repeated freeze-thaw cycles also reduce reliability.
Quality control for glutathione materials checks identity, assay, purity, water content, and disulfide content. Commercial products vary from research-grade powder to dietary supplements, and labels may not distinguish reduced from oxidized forms. In the United States, oral glutathione is commonly sold as a dietary supplement rather than an approved drug, while injectable forms fall under different rules and may require a prescription. Regulatory status differs by country. Analytical certificates, when available, help verify what a material contains, but independent testing remains important for interpretation.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS/MS, HPLC, or enzymatic recycling | Choice depends on whether total, reduced, or oxidized glutathione is measured. |
| Sample stabilization | Acidification or thiol alkylation | Helps limit conversion of GSH to GSSG after collection. |
| Solution stability | Limited at room temperature | Oxidation and pH-dependent degradation can occur. |
| Storage of solid | -20 °C, desiccated, protected from light | Common for research reagents; follow supplier instructions. |
| Common interference | Other thiols and metal ions | Can affect separation or enzymatic detection. |
Quantifying glutathione requires distinguishing GSH from GSSG and preventing oxidation during sample preparation. Common approaches include the enzymatic recycling assay, often called the Tietze method, which measures total glutathione after converting GSSG to GSH. HPLC with ultraviolet or fluorescence detection and LC-MS/MS can separate and quantify both forms, sometimes after derivatization of the thiol group. Blood, plasma, and tissue samples differ in matrix and baseline concentrations, so method validation must account for recovery, linearity, and interference. No single assay is universally standard.
Glutathione is most stable as a dry powder stored cool and dry, but its thiol group is readily oxidized in solution. Aqueous preparations at neutral or alkaline pH lose GSH faster because the thiolate form reacts with dissolved oxygen and metal ions. Acidic conditions, chelating agents, and oxygen exclusion can slow oxidation, while repeated freeze-thaw cycles promote degradation. Light exposure and trace metals also contribute to loss. Laboratories typically validate stability for their own matrices because degradation rates depend on pH, temperature, concentration, and container materials.
Commercial glutathione is available in research-grade, food-grade, and supplement-grade forms, and purity specifications differ accordingly. Certificates of analysis commonly report identity by nuclear magnetic resonance or mass spectrometry, purity by HPLC, residual solvents, and heavy metals. Reference standards with assigned purity support calibration, while isotopically labeled glutathione can serve as an internal standard for mass spectrometry. For supplements, label claims may not be independently verified, and regulatory oversight varies by country. Verification often involves third-party testing for identity, potency, and contaminants.
Measuring glutathione in biological samples requires attention to oxidation and matrix effects. High-performance liquid chromatography with ultraviolet or fluorescence detection can separate reduced and oxidized forms after derivatization. Liquid chromatography with tandem mass spectrometry offers higher specificity and can quantify glutathione alongside related thiols. Because glutathione can oxidize during sample handling, many protocols use rapid acidification with metaphosphoric acid or sulfosalicylic acid. Internal standards help correct for losses during extraction and analysis.
Enzymatic recycling assays provide a complementary approach for total glutathione. In these methods, glutathione reductase reduces oxidized glutathione while a thiol-reactive reagent, such as 5,5'-dithiobis(2-nitrobenzoic acid), produces a colored product. The reaction cycles between reduced and oxidized forms, amplifying the signal. Spectrophotometric or fluorometric detection can then estimate concentration. Distinguishing reduced glutathione from glutathione disulfide often requires separate aliquots, masking agents, or chromatographic separation, and the choice affects reported values.
Storage conditions strongly influence glutathione stability. The solid reduced form is commonly kept desiccated at or below minus twenty degrees Celsius, protected from light and moisture. Aqueous solutions are less stable because the thiol group reacts with dissolved oxygen, and oxidation accelerates at neutral or alkaline pH. Acidic solutions and oxygen-free handling can slow degradation, but repeated freeze-thaw cycles should be avoided. Researchers often verify concentration before use, because apparent losses can arise from oxidation or water uptake.
== History == Orthologs of AgRP, ASIP, MCIR, and MC4R have been found in mammalian, teleost fish, and avian genomes. This suggests that the agouti-melanocortin system evolved by gene duplication from individual ligand and receptor genes in the last 500 million years.
=== Hypoglycemia === Hypoglycemia, or abnormally low blood glucose, is an acute complication of several diabetes treatments. It is rare otherwise, either in diabetic or non-diabetic patients. The patient may become agitated, sweaty, weak, and have many symptoms of sympathetic activation of the autonomic nervous system resulting in feelings akin to dread and immobilized panic. Consciousness can be altered or even lost in extreme cases, leading to coma, seizures, or even brain damage and death. In patients with diabetes, this may be caused by several factors, such as too much or incorrectly timed insulin, too much or incorrectly timed exercise (exercise decreases insulin requirements) or not enough food (specifically glucose containing carbohydrates). The variety of interactions makes cause identification difficult in many instances. It is more accurate to note that iatrogenic hypoglycemia is typically the result of the interplay of absolute (or relative) insulin excess and compromised glucose counterregulation in type 1 and advanced type 2 diabetes. Decrements in insulin, increments in glucagon, and, absent the latter, increments in epinephrine are the primary glucose counterregulatory factors that normally prevent or (more or less rapidly) correct hypoglycemia. In insulin-deficient diabetes (exogenous) insulin levels do not decrease as glucose levels fall, and the combination of deficient glucagon and epinephrine responses causes defective glucose counterregulation. Furthermore, reduced sympathoadrenal responses can cause hypoglycemia unawareness.
=== Molecular biology === In 2023, researchers at the University of California, San Francisco presented Thagomizer, a modality for the interrogation of RNA-protein binding events in CLIP-Seq (Cross-linking and immunoprecipitation) data.
Increasingly restrictive drug laws of the 1960s and the 1970s curbed scientific research into the effects of psilocybin and other hallucinogens, but its popularity as an entheogen grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and psilocybin is classified as a Schedule I controlled substance in the 1971 United Nations Convention on Psychotropic Substances. Psilocybin is being studied as a possible medicine in the treatment of psychiatric disorders such as major depressive disorder, substance use disorders, obsessive–compulsive disorder, and other conditions such as cluster headaches. Psilocybin was approved for treatment-resistant depression in Australia in 2023. It is in late-stage clinical trials in the United States for major depressive disorder and treatment-resistant depression. As of September 2026, complete submission of psilocybin for treatment-resistant depression is expected in the fourth quarter of 2026 and commercial launch for this indication is anticipated in the first half of 2027. Especially at higher doses and combined with psychological support, single doses of psilocybin may produce rapid and long-lasting antidepressant effects that outperform placebo, though they may produce either modest or no effectiveness advantage over continuous use of selective serotonin reuptake inhibitors (SSRIs) like escitalopram and trial methodological issues are common.
Sources: en.wikipedia.org
== Mechanisms of action == Agmatine was found to exert modulatory actions directly and indirectly at multiple key molecular targets underlying cellular control mechanisms of cardinal importance in health and disease. The following outline indicates the categories of control mechanisms, and identifies their molecular targets:
Proteins are often thought of as relatively stable tertiary structures that experience conformational changes after being affected by interactions with other proteins or as a part of enzymatic activity. However, proteins may have varying degrees of stability, and some of the less stable variants are intrinsically disordered proteins. These proteins exist and function in a relatively 'disordered' state lacking a stable tertiary structure. As a result, they are difficult to describe by a single fixed tertiary structure. Conformational ensembles have been devised as a way to provide a more accurate and 'dynamic' representation of the conformational state of intrinsically disordered proteins. Protein ensemble files are a representation of a protein that can be considered to have a flexible structure. Creating these files requires determining which of the various theoretically possible protein conformations actually exist. One approach is to apply computational algorithms to the protein data in order to try to determine the most likely set of conformations for an ensemble file. There are multiple methods for preparing data for the Protein Ensemble Database that fall into two general methodologies – pool and molecular dynamics (MD) approaches (diagrammed in the figure). The pool based approach uses the protein's amino acid sequence to create a massive pool of random conformations. This pool is then subjected to more computational processing that creates a set of theoretical parameters for each conformation based on the structure.
Patients who do not drink may require fluids by nasogastric tube. Intravenous fluids are recommended only in those who have significant dehydration due to their potential complications, including congestive heart failure.
Sources: en.wikipedia.org
The ancient Greeks postulated whether parts of the body could be regenerated in the 700s BC. Skin grafting, invented in the late 19th century, can be thought of as the earliest major attempt to recreate bodily tissue to restore structure and function. Advances in transplanting body parts in the 20th century further pushed the theory that body parts could regenerate and grow new cells. These advances led to tissue engineering, and from this field, the study of regenerative medicine expanded and began to take hold. This began with cellular therapy, which led to the stem cell research that is widely being conducted today. The first cell therapies were intended to slow the aging process. This began in the 1930s with Paul Niehans, a Swiss doctor who was known to have treated famous historical figures such as Pope Pius XII, Charlie Chaplin, and king Ibn Saud of Saudi Arabia. Niehans would inject cells of young animals (usually lambs or calves) into his patients in an attempt to rejuvenate them. In 1956, a more sophisticated process was created to treat leukemia by inserting bone marrow from a healthy person into a patient with leukemia. This process worked mostly due to both the donor and receiver in this case being identical twins. Nowadays, bone marrow can be taken from people who are similar enough to the patient who needs the cells to prevent rejection. The term "regenerative medicine" was first used in a 1992 article on hospital administration by Leland Kaiser. Kaiser's paper closes with a series of short paragraphs on future technologies that will impact hospitals.
=== Counterfeit impact factors === Fake impact factors or bogus impact factors are produced by certain companies or individuals. According to an article published in the Electronic Physician, these include Global Impact Factor, Citefactor, and Universal Impact Factor. Jeffrey Beall maintained a list of such misleading metrics. Another deceitful practice is reporting "alternative impact factors", calculated as the average number of citations per article using citation indices other than JCR such as Google Scholar (e.g., "Google-based Journal Impact Factor") or Microsoft Academic. False impact factors are often used by predatory publishers. Consulting Journal Citation Reports' master journal list can confirm if a publication is indexed by the Journal Citation Reports. The use of fake impact metrics is considered a red flag.
=== Distribution === Estradiol is rapidly distributed throughout the body, with a distribution phase of about 6 minutes following intravenous injection. Estradiol is taken up into cells via passive diffusion due to its lipophilicity. Due to binding to the ERs, estradiol is preferentially concentrated in tissues with the highest ER content. In animals, these tissues have included the uterus, vagina, mammary glands, pituitary gland, hypothalamus, other brain regions, adipose tissue, liver, and adrenal glands, among other tissues. In contrast to estradiol, due to its low affinities for the ERs, estrone is not accumulated in target tissues. Estradiol has been found to cross the blood–brain barrier in rhesus monkeys. The volume of distribution of estradiol has been found to be 0.85 to 1.17 L/kg. In another study however, its volume of distribution was only 0.082 ± 0.015 L/kg (4.8 L in women of average weight 58.4 kg). In terms of plasma protein binding, estradiol is bound loosely to albumin and tightly to SHBG, with approximately 97 to 98% of estradiol bound to plasma proteins. In the circulation, approximately 38% of estradiol is bound to SHBG and 60% is bound to albumin, with 2 to 3% free or unbound. However, with oral estradiol, there is an increase in hepatic SHBG production and hence SHBG levels (e.g., +50%), and this results in a relatively reduced fraction of free estradiol. As only free estradiol that is not bound to plasma proteins or SHBG is biologically active, this may reduce the potency of oral estradiol by some degree.
Sources: en.wikipedia.org
Preanalytical factors such as sample type, time to processing, and stabilization method can change GSH and GSSG amounts. Analytical method and calibration also contribute to variation. Comparing absolute values across studies requires caution.
These assays typically measure total glutathione after oxidizing or reducing steps convert GSSG to GSH. A colorimetric or fluorometric signal is proportional to the recycling reaction. They generally do not report GSH and GSSG separately unless additional steps are used.
Solutions are often prepared fresh and kept cold, with protection from light and oxygen exposure. Chelating agents may reduce metal-catalyzed oxidation. Storage recommendations vary by buffer, pH, and concentration, so protocol-specific guidance should be followed.
Common approaches include enzymatic recycling assays, HPLC, and LC-MS/MS. Acid extraction and rapid processing limit oxidation before analysis.